PepVax Announces Completion of Efficacy Study with Key Pre-Clinical Data to Validate PVX-009, Addition to its Advisory Board and Other Updates

Saturday, January 6, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., Jan. 5, 2018 /PRNewswire/ -- PepVax, Inc., an early-stage biotechnology company, announced today that it has

successfully completed the efficacy study for its lead candidate, PVX-009. The Company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a treatment for triple negative breast cancer (TNBC).

PepVax

has made serious and very important strides in compliance with the requirements of the US FDA to evaluate efficacy in animals towards human clinical trials. Expected efficacy outcomes in PVX-009 have been established and will be moving towards larger combination in vivo trials with checkpoint inhibitors.   

The effectiveness of the DNA immunotherapy uses precise immunogenic regions identified from the tumor-specific protein, MAGE A, to induce a strong immune response toward MAGE A expressing cancer cells. "With these results, we are confident in moving forward with our IND-enabling studies, along with combination trials, and expect to file an IND in the next eighteen months," stated Mahesh Narayanan, CEO of PepVax.

PepVax also announced today the addition of a new member to the PepVax Advisory Board, Mr. Sunil Joshi.  Mr. Joshi has over 25 years of experience in the biopharmaceutical industry and has strong expertise in oncology drug development and commercialization. He most recently served as the Chief Executive Officer and President of Gradalis, Inc.

Moreover, PepVax announced today the Company's Chief Executive Officer, Mahesh Narayanan, will attend the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 7-12, 2018. PepVax has a full schedule of meetings in which Mr. Narayanan will present to and update potential institutional investors, pharmaceutical companies, and the life science media with and about PepVax' platform technology in the treatment of TNBC and other cancers.

About PepVax, Inc. PepVax, Inc. was founded in 2013 to harness the power of the human immune system to treat cancer. The Company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.pepvax.co

Cision View original content:http://www.prnewswire.com/news-releases/pepvax-announces-completion-of-efficacy-study-with-key-pre-clinical-data-to-validate-pvx-009-addition-to-its-advisory-board-and-other-updates-300578469.html

SOURCE PepVax, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store